---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-100714"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:53:31.147663+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika enters cooperation with Caligan, appoints director, authorizes $20M buyback

## Summary
- Appointed Gary Fischetti as Class III director; Board expands to eight members.
- Authorized $20M share repurchase: $5M accelerated, $5M open market, $10M subject to positive cash flow.
- Formed Capital Allocation Committee with Fischetti, Henneman, and Thompson.
- Caligan agreed to standstill and voting commitments supporting Board's 2023 slate.

## SEC filing metadata
- accession: 0001193125-23-100714
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/0001193125-23-100714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/d438476d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-100714
- JSON: https://secwatch.observer/filing/0001193125-23-100714.json
- Plain text: https://secwatch.observer/filing/0001193125-23-100714.txt

## Key facts
- Executive change
  Gary Fischetti was appointed as Class III director at Anika Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: effective April 13, 2023, the Board of the Company increased its size from seven to eight directors and appointed Mr. Fischetti to the Board as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/0001193125-23-100714-index.htm
- Material Agreements
  Anika Therapeutics, Inc. entered into Cooperation Agreement with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the 'Investor Group') valued at $20,000,000 (effective 2023-04-13).
  - Action: entry
  - Counterparty: Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the 'Investor Group')
  - Value: $20,000,000
  - Effective: 2023-04-13
  source text: On April 13, 2023, Anika Therapeutics, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the “Investor Group”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/0001193125-23-100714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.